Printer Friendly

EISAI AND GENPHARM COLLABORATE ON HUMAN ANTIBODY THERAPEUTIC

 MOUNTAIN VIEW, Calif., June 23 /PRNewswire/ -- GenPharm International announced today the signing of a collaboration agreement with Eisai Co. Ltd. on a specific human antibody product from GenPharm's novel technology for generating completely human antibodies from transgenic mice. Under the agreement, GenPharm will be responsible for development and initial manufacturing of the antibody product. Eisai will make research and milestone payments up to $25 million, assuming that all the benchmarks are successfully met and the product receives approval in Japan for therapeutic use. In return Eisai will receive exclusive marketing rights for Asia as well as certain manufacturing rights. GenPharm will also receive royalty payments from Eisai when the antibody product is commercialized. The target of the antibody product was not announced.
 "This agreement with Eisai confirms GenPharm's leadership position in the development of completely human antibodies using transgenic mice," commented Jonathan J. MacQuitty, chief executive officer of GenPharm International. "We expect this and other collaborations to help further the development and commercialization of GenPharm's antibody products as we move towards specific therapeutic targets."
 GenPharm has developed its novel technology around proprietary transgenic mice which can generate a wide range of human antibodies. These mice have been generated by a series of complex genetic modifications including the inactivation of the mouse antibody genes and the addition of unrearranged human antibody genes. The resulting mice can be immunized with a wide variety of antigens to produce human antibodies for therapeutic and diagnostic applications.
 Eisai is a leading Japanese human healthcare company headquartered in Tokyo. Eisai has significant marketing operations in Southeast Asia as well as research and development activities in the United States and the United Kingdom including clinical research and basic discovery research. Eisai in its "Pursuit of Excellence" has invested in new technologies in order to create superior pharmaceutical products for the future.
 GenPharm International is a leading biotechnology company focused on using transgenic animal technology for human healthcare products. GenPharm's U.S. operation, based in Mountain View, is developing completely human monoclonal antibodies from transgenic mice, as well as developing and marketing transgenic animal models for drug discovery and drug testing.
 -0- 6/22/93
 /CONTACT: Jonathan J. MacQuitty, chief executive officer of GenPharm International, 415-964-7024/


CO: GenPharm International Inc.; Eisai Co. Ltd. ST: California IN: MTC SU:

TM-GT -- SJ002 -- 4615 06/22/93 14:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1993
Words:389
Previous Article:BETHLEHEM STEEL'S CHAIRMAN SAYS INTEGRATED STEEL MILLS 'CAN AND WILL COMPETE' WITH NEW THIN-SLAB MINIMILLS
Next Article:RUMORED FOREST MANAGEMENT RECOMMENDATIONS UNACCEPTABLE, SAYS LABOR LEADER
Topics:


Related Articles
ISIS PHARMACEUTICALS AND EISAI AGREE TO CODEVELOP ANTISENSE DRUG
IDEC PHARMACEUTICALS AND EISAI TO DEVELOP ANTIBODY TREATMENT FOR AUTOIMMUNE DISEASE
Isis and Eisai Agree to Provide Full Commercial Rights to Isis on CMV Retinitis Compound
Medarex To Acquire GenPharm
Bristol-Myers Squibb And Medarex Announce HuMAb-Mouse(TM) Collaboration
Medarex Receives Patent for High Affinity Human Antibodies
MorphoSys and LeukoSite Sign Collaboration Agreement
Medarex Receives Milestone Payment from Eisai Co., Ltd.
Medarex Announces Antibody Development Agreement with Medac

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters